8-K
filed June 21, 2023, 7:59 PM ET
ticker AVIR
CIK 0001593899
other material
confidence high
sentiment neutral
materiality 0.25
Atea Pharmaceuticals amends bylaws and reports annual meeting voting results
Atea Pharmaceuticals, Inc.
- Bylaws amended to adopt universal proxy rules and enhance stockholder nomination disclosure.
- Directors Jerome Adams and Barbara Duncan elected with 34.5M and 40.6M votes for, respectively.
- Advisory vote on executive compensation approved with 40M for (70% of votes cast).
- Ratification of KPMG as auditor approved with 64.5M for, 6.3M against.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Atea Pharmaceuticals, Inc.: Amended restated bylaws to address universal proxy rules, enhance stockholder nomination and proposal disclosure requirements, and require non-white proxy card color for stockholder solicitations (effective 2023-06-16).
- Change
- bylaw amendment
- Effective
- 2023-06-16
Exact text from the filing
On June 16, 2023, the Board of Directors (“Board”) of Atea Pharmaceuticals, Inc. (the “Company”) amended the Company’s amended and restated bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day. Among other things, the Amended and Restated Bylaws: • address the universal proxy rules adopted by the U.S. Securities and Exchange Commission (the “SEC”), by clarifying that no person may solicit proxies in support of a director nominee other than the Board’s nominees unless such person has complied with Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including applicable notice and solicitation requirements; • enhance procedural mechanics and disclosure requirements in connection with stockholder nominations of directors and submissions of proposals regarding other business at stockholder meetings (other than proposals to be included in the Company’s proxy materials pursuant to Rule 14a-8 under Exchange Act), inclu
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Atea Pharmaceuticals, Inc. shareholders approved Advisory (non-binding) approval of the compensation of the Company’s named executive officers at the 2022-06-16 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2022-06-16
Exact text from the filing
Item 3 — Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 40,032,147 15,511,146 1,437,152 13,840,079
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Atea Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2022-06-16 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2022-06-16
Exact text from the filing
Item 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 64,494,470 6,285,533 40,521 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
Atea Pharmaceuticals, Inc. shareholders approved Election of two Class III Directors to serve until the 2026 Annual Meeting of Stockholders at the 2022-06-16 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2022-06-16
Exact text from the filing
Item 1 — Election of two Class III Directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Jerome Adams, M.D. 34,544,693 22,435,752 13,840,079 Barbara Duncan 40,592,669 16,387,776 13,840,079
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.